ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Alzamend Neuro, Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026
$1.33+0.03 (+2.31%)
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
Alzamend Neuro, Inc. cash flow statement
Ratios
Latest available, balances at Jul 31, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2026
- -373.2%
Financial strength
- Current ratio
- –
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- –
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.03
- Dividend yield
- –